ethyl α-maltoside

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl α-maltoside
• 英文别名: ethyl-α-maltoside；Glc(a1-4)Glc(a)-O-Et；(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-ethoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₁₄H₂₆O₁₁
• 分子量: 370.354
• InChiKey: KTBPXDPDLAKMMM-SASNSOKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  179
• 氢给体数：
  7
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  乙醇 、 麦芽糖 在 recombinant Aspergillus oryzae α-glucosidase 作用下， 以 aq. acetate buffer 为溶剂， 反应 48.0h， 生成 ethyl α-maltoside 、 ethyl α-isomaltoside
  参考文献：
  名称：

  在米酒中，米曲霉的α-葡萄糖苷酶A在酿造过程中，转糖基化形成了新型的糖苷乙基α-麦芽糖苷和乙基α-异麦芽糖苷。

  摘要：

  日本米酒Sake中含有多种由发酵过程中的真菌酶产生的低聚糖和葡糖苷。这项研究研究了敲除米曲霉α-葡萄糖苷酶（agdA）基因对酿造清酒中转糖基化产物的影响。除了α-乙基葡糖苷和α-甘油基葡糖苷外，通过agdA基因敲除，具有与乙基麦芽糖相似的分子量值的两种化合物的量也减少了。两种化合物均由麦芽糖和乙醇与纯化的agdA体外合成。核磁共振分析确定了两种化合物，分别是乙基α-麦芽糖苷和乙基α-异麦芽糖苷，无论是在自然环境还是在自然环境中，都是新颖的化合物。

  DOI：

  10.1021/acs.jafc.9b06936

文献信息

• Metal-catalyzed Stereoselective and Protecting-group-free Synthesis of 1,2-<i>cis</i>-Glycosides Using 4,6-Dimethoxy-1,3,5-triazin-2-yl Glycosides as Glycosyl Donors
  作者：Tomonari Tanaka、Naoya Kikuta、Yoshiharu Kimura、Shin-ichiro Shoda

  DOI：10.1246/cl.150201

  日期：2015.6.5

  4,6-Dimethoxy-1,3,5-triazin-2-yl glycosides, glycosyl donors prepared in one step from free saccharides without protection of the hydroxy groups, were stereoselectively and equivalently converted t...

  4,6-二甲氧基-1,3,5-triazin-2-yl 糖苷，由游离糖一步制备的糖基供体，没有羟基保护，立体选择性地等价转化为...
• PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT
  申请人：Lee May Dean-Ming

  公开号：US20100297020A1

  公开（公告）日：2010-11-25

  Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.

  本文描述了通过给予吡喃类似物或其衍生物的方法来治疗和预防代谢性疾病或其他疾病。还描述了通过给予吡喃类似物或其衍生物与一个或多个额外的药物如降脂药或降糖药组合的方法来治疗和预防代谢性疾病和其他疾病。本文还描述了调节脂质转运蛋白活性以增加生理区域中脂质向外部环境的外流的方法。本文所披露的方法可用于评估在给予吡喃类似物或其衍生物后治疗或预防代谢性疾病的效果。
• METHODS AND COMPOSITIONS FOR TREATING PAIN
  申请人：Robbins Wendye

  公开号：US20070087977A1

  公开（公告）日：2007-04-19

  Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments.
• SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS
  申请人：LEE Ving

  公开号：US20090082400A1

  公开（公告）日：2009-03-26

  Methods and compositions are described that comprise pyrone analogs such as flavonoids and cyclodextrins including quercetin and quercetin derivatives and sulfoalkyl ether cyclodextrins. In some cases the compounds of the invention are administered with a therapeutic agent such as an analgesic. In some cases, treatment with the compositions of the invention can result in the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compositions out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compositions from physiological compartments, including central nervous system and fetal compartments.
• Methods and compositions for therapeutic treatment
  申请人：Robbins Wendye

  公开号：US20090325906A1

  公开（公告）日：2009-12-31

  Methods and compositions are described for the modulation of hyperglycemia and/or one or more symptoms of hyperglycemia. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity to increase the efflux of calcineurin inhibitor from physiological compartments.